Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation

Transplant Infectious Disease

Volumn 9, Issue 2, 2007, Pages 156-160

  Gupta, S ^a   Almyroudis, N G ^a,b   Battiwalla, M ^a,b   Bambach, B J ^a,b   McCarthy, P L ^a,b   Proefrock, A D ^b   Ball, D ^b   Paplham, P ^b   Varma, A ^c   Kwon Chung, J ^c   Segal, B H ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Fusarium; Hematopoietic stem cell transplantation; Mold; Posaconazole; Transplant

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CYTOTOXIC AGENT; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; TACROLIMUS; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FUSARIOSIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; LOW DRUG DOSE; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; SKIN DISEASE; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ADOLESCENT; ANTIFUNGAL AGENTS; FEMALE; FUSARIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MYCOSES; NEUTROPENIA; TRIAZOLES;

EID: 34247617408     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2006.00189.x     Document Type: Article

References (16)

1. Kontoyiannis DP, Bodey GP, Hanna H, et al. Outcome determinants of fusariosis in a tertiary care center: the impact of neutrophil recovery. Leuk Lymphoma 2004 45: 139 141.
2. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997 90: 999 1008.
3. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002 34: 909 917.
4. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004 38: 1237 1242.
5. Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999 43: 589 591.
6. Herbrecht R, Kessler R, Kravanja C, Meyer MH, Waller J, Letscher-Bru V. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004 23: 1451 1454.
7. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematological malignancy and other conditions. Clin Infect Dis 2006 46: 1398 1403.
8. Raad I, Chapman S, Bradsher R, et al. Posaconazole (POS) salvage therapy for invasive fungal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2004, Washington, DC (Abstract M-669).
9. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005 5: 775 785.
10. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease with invasive filamentous fungal infection. Clin Infect Dis 2005 40: 1684 1688.
11. Woloshuk CP, Yousibova GL, Rollins JA, Bhatnagar D, Payne GA. Molecular characterization of the afl-1 locus in Aspergillus flavus. Appl Environ Microbiol 1995 61: 3019 3023.
12. Hue FX, Huerre M, Rouffault MA, de Bievre C. Specific detection of fusarium species in blood and tissues by a PCR technique. J Clin Microbiol 1999 37: 2434 2438.
13. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agent Chemother 2002 46: 3298 3330.
14. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole (POS) vs. fluconazole (FLU) for prophylaxis for invasive fungal infections (IFIs) in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD): results of a multicenter trial. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, 2005, Washington, DC (Abstract M-716).
15. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole (POS) vs standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): impact on mortality. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, 2005, Washington, DC (Abstract 722-b).
16. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006 173: 707 717.